Soon-Shiong immuno-oncology startup NantCell rakes in $57M
Another load of cash - and little further insight - is on the books for Patrick Soon-Shiong cancer immunotherapy startup NantCell.
Another load of cash - and little further insight - is on the books for Patrick Soon-Shiong cancer immunotherapy startup NantCell.
Dr. Patrick Soon-Shiong has two more fundraises under his companies' belt: According to an SEC filing, immuno-oncology startup NantCell has raised $100 million and precision medicine startup NantOmics has raised $150 million.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The mysterious company just allocated $75 million to its NantCell division - putting some serious funding behind its precision medicine and cancer immunotherapy efforts.